Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: A decline since 2003

Cancer Epidemiology

Volumn 34, Issue 3, 2010, Pages 238-243

  Fontenoy, A M ^a   Leux, C ^a   Delacour Billon, S ^a   Allioux, C ^b   Frenel, J S ^c   Campone, M ^c   Molinie F ^a  

^a Registre des cancers de Loire Atlantique et de Vendée ^*  (France)

^b Structure de gestion du dépistage organisé en Loire Atlantique   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Breast cancer; Epidemiology; Hormone replacement therapy; Incidence; Mammography

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER REGISTRY; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FRANCE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREND STUDY;

AGED; BREAST NEOPLASMS; FEMALE; FRANCE; HUMANS; INCIDENCE; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME;

EID: 77952238848     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.03.007     Document Type: Article

References (42)

1. Ravdin P.M., Cronin K.A., Howlader N., Berg C.D., Chlebowski R.T., Feuer E.J., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
2. Johnston M. Breast cancer drop linked to fall in use of HRT. http://www.nzherald.co.nz/health/news/article.cfm?c_id=204&objectid=10416198; 2006.
3. Canfell K., Banks E., Moa A.M., and Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188 (2008) 641-644
4. Vankrunkelsven P., Kellen E., Lousbergh D., Cloes E., Op de Beeck L., Faes C., et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 118 (2009) 425-432
5. Katalinic A., and Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107 (2008) 427-430
6. Kerlikowske K., Miglioretti D.L., Buist D.S., Walker R., and Carney P.A. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99 (2007) 1335-1339
7. Li C.I., and Daling J.R. Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16 (2007) 2773-2780
8. Zanetti R., Ponti A., Rosso S., Ricceri F., Pitarella S., and Segnan N. The beginning of a decline in breast cancer incidence in Italy?. Tumori 94 (2008) 293-296
9. Allemand H., Seradour B., Weill A., and Ricordeau P. Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer 95 (2008) 11-15
10. Séradour B., Allemand H., Weill A., and Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer 96 (2009) E1-E6
11. IARC. Standards and guidelines for cancer registration in Europe: the ENCR recommendations vol. 1 (2008), IARC, Lyon
12. Ferlay J, Burkhard C, Whelan S, Parkin DM. Check and conversion programs for cancer registries (IARC/IACR Tools for Cancer Registries). IARC Technical Report No. 42, Lyon; 2005.
13. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0; 2008.
14. Belot A., Grosclaude P., Bossard N., Jougla E., Benhamou E., Delafosse P., et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 56 (2008) 159-175
15. Karim-Kos H.E., de Vries E., Soerjomataram I., Lemmens V., Siesling S., and Coebergh J.W. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44 (2008) 1345-1389
16. Hery C., Ferlay J., Boniol M., and Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 19 (2008) 1009-1018
17. Bouchardy C., Usel M., Verkooijen H.M., Fioretta G., Benhamou S., Neyroud-Caspar I., et al. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Cancer Res Treat 120 (2009) 519-523
18. Soerjomataram I., Coebergh J.W., Louwman M.W., Visser O., and van Leeuwen F.E. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands?. J Clin Oncol 25 (2007) 5038-5039 [author reply 5039-40]
19. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 372 (2008) 608-610
20. Zahl P.H., and Maehlen J. A decline in breast-cancer incidence. N Engl J Med 357 (2007) 510-511 [author reply 513]
21. Glass A.G., Lacey Jr. J.V., Carreon J.D., and Hoover R.N. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99 (2007) 1152-1161
22. Cap santé plus. Rapport d'activité de l'année 2008; 2009.
23. Clarke C.A., and Glaser S.L. Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control 18 (2007) 847-852
24. Hausauer A.K., Keegan T.H., Chang E.T., and Clarke C.A. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype. Breast Cancer Res 9 (2007) R90
25. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 (2004) 47-53
26. Parkin D.M. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?. Eur J Cancer 45 (2009) 1649-1653
27. Dietel M., Lewis M.A., and Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20 (2005) 2052-2060
28. French Health Products Safety Agency (Afssaps). Hormone replacement therapy. http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-de-sante/Traitement-hormonal-substitutif-de-la-menopause-THS; 2003.
29. French Health Products Safety Agency (Afssaps). Report on hormonal replacement therapy for menopause. http://www.afssaps.fr/Infos-de-securite/Communiques-de-presse/Donnees-francaises-sur-le-traitement-hormonal-substitutif-de-la-menopause-THS; 2005.
30. Campagnoli C., Clavel-Chapelon F., Kaaks R., Peris C., and Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 96 (2005) 95-108
31. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107 (2008) 103-111
32. Collins J.A., Blake J.M., and Crosignani P.G. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11 (2005) 545-560
33. Fournier A., Fabre A., Mesrine S., Boutron-Ruault M.C., Berrino F., and Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 26 (2008) 1260-1268
34. Li C.I., Malone K.E., Porter P.L., Weiss N.S., Tang M.T., Cushing-Haugen K.L., et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 (2003) 3254-3263
35. Lee S., Kolonel L., Wilkens L., Wan P., Henderson B., and Pike M. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer 118 (2006) 1285-1291
36. Jemal A., Ward E., and Thun M.J. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9 (2007) R28
37. Daling J.R., Malone K.E., Doody D.R., Voigt L.F., Bernstein L., Coates R.J., et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95 (2002) 2455-2464
38. Chen C.L., Weiss N.S., Newcomb P., Barlow W., and White E. Hormone replacement therapy in relation to breast cancer. JAMA 287 (2002) 734-741
39. Newcomer L.M., Newcomb P.A., Potter J.D., Yasui Y., Trentham-Dietz A., Storer B.E., et al. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14 (2003) 225-233
40. Rosenberg L.U., Granath F., Dickman P.W., Einarsdottir K., Wedren S., Persson I., et al. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res 10 (2008) R78
41. Sener S.F., Winchester D.J., Winchester D.P., Du H., Barrera E., Bilimoria M., et al. The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. Am J Surg 197 (2009) 403-407
42. Ringa V., and Fournier A. Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)?. Rev Epidemiol Sante Publique 56 (2008) 297-301